Novel Therapies in Hepatitis C Virus, an Issue of Clinics in Liver Disease PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Novel Therapies in Hepatitis C Virus, an Issue of Clinics in Liver Disease PDF full book. Access full book title Novel Therapies in Hepatitis C Virus, an Issue of Clinics in Liver Disease by Paul J. Pockros. Download full books in PDF and EPUB format.
Author: Paul J. Pockros
Publisher: Saunders
ISBN: 9781437712360
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
The Guest Editor presents state-of-the-art articles devoted to therapies for treatment of HCV. The novel therapies addressed in this issue include interferons, viral kinetics and anti-viral resistence, anti-fibrotics, immunotherapeutics, hepatoprotectants and caspace inhibitors, and cyclosporine analogues, to name a few.
Author: Paul J. Pockros
Publisher: Elsevier Health Sciences
ISBN: 1455771988
Category : Medical
Languages : en
Pages : 245
Get Book Here
Book Description
Dr. Pockros has created a clinically focused issue based on the CONO 2012 meeting, whereby he was able to have those presenters write articles for his issue. Therefore, the content for HCV in this issue reflects the most current knowledge. The issue is focused on basic/current information, current therapy and special populations, triple and quad combination therapies in development, and an article on second generation protease inhibitors. The reader can expect that this issue will provide thorough clinical reviews on the most current therapeutic options for HCV.
Author: Paul J. Pockros
Publisher: Saunders
ISBN: 9781437712360
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
The Guest Editor presents state-of-the-art articles devoted to therapies for treatment of HCV. The novel therapies addressed in this issue include interferons, viral kinetics and anti-viral resistence, anti-fibrotics, immunotherapeutics, hepatoprotectants and caspace inhibitors, and cyclosporine analogues, to name a few.
Author: Paul J. Pockros
Publisher: Clinics: Internal Medicine
ISBN: 9781455771127
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
Dr. Pockros has created a clinically focused issue based on the CONO 2012 meeting, whereby he was able to have those presenters write articles for his issue. Therefore, the content for HCV in this issue reflects the most current knowledge. The issue is focused on basic/current information, current therapy and special populations, triple and quad combination therapies in development, and an article on second generation protease inhibitors. The reader can expect that this issue will provide thorough clinical reviews on the most current therapeutic options for HCV.
Author: Barbara McGovern
Publisher: Elsevier Health Sciences
ISBN: 145574719X
Category : Medical
Languages : en
Pages : 240
Get Book Here
Book Description
Hepatitis C infection can be an acute or chronic illness and is the most common cause of liver disease in the US. It often goes undiagnosed until significant organ damage has occurred. This issue of the ID Clinics discusses the staging of liver disease, treatments for those newly diagnosed, and those who are dealing with chronic illness, along with managing drug therapy and virus resistance.
Author: Fred Poordad
Publisher: Elsevier Health Sciences
ISBN: 0323413374
Category : Medical
Languages : en
Pages : 145
Get Book Here
Book Description
Clinical information about Hepatitis C is quickly outdated, so Dr. Poordad has assembled expert authors to provide state-of-the-art clinjcal reviews for hepatologists. This issue is uniquely organized to present articles based on therapeutic regimens for certain types of patients: Regimens for the Treatment-Naïve Patient; Regimens for Treatment of the Interferon-Failure Patient; Regimens for DAA Failure Patients; Regimens for the Cirrhotic Patient; Regimens for the Peri-Transplant Patient; Regimens for the HIV-Co-Infected Patient; and Next-generation Regimens: The Future of HCV Therapy. This presentation will be very clinically relevant for the practicing hepatologist.
Author: K. Rajender Reddy
Publisher: Elsevier Health Sciences
ISBN: 0323402496
Category : Medical
Languages : en
Pages : 249
Get Book Here
Book Description
There are over 180 million people with chronic HCV infection worldwide with between 2.7 and 3.9 million in the United States. Hepatitis C most significantly affects Asia and Africa, with rates up to 15% in countries such as Egypt and up to 30% in certain regions such as Punjab, Pakistan. Hepatitis C places a significant burden on the public health infrastructure, as it remains the leading cause of chronic liver disease, accounting for 50-75% of primary liver cancers and is responsible for 30% of all liver transplantations. It is estimated to have cost the United States $5.5 billion in 1997, comparable to the national cost of asthma, $5.8 billion in 1994.This number is only expected to grow as the current HCV population ages, increasing overall rates of compensated cirrhosis/end-stage liver disease. The evolution of directly acting anti-virals has ushered in a new era for chronic hepatitis C. Ongoing drug development strategy has involved targeting several replication steps of the virus and the hope is to see all oral therapies by late 2014 or early 2015. Thus we are at an exciting cross roads with regard to new information and challenges with HCV: rising disease burden with associated high costs, the challenges globally and in multiple patient populations, and the impending availability of effective and well tolerated treatments. Therefore there is a need to commission an exclusive issue of GCNA for HCV.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309438020
Category : Medical
Languages : en
Pages : 187
Get Book Here
Book Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
Author: Barbara McGovern
Publisher: Saunders
ISBN: 9781455748990
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
Hepatitis C infection can be an acute or chronic illness and is the most common cause of liver disease in the US. It often goes undiagnosed until significant organ damage has occurred. This issue of the ID Clinics discusses the staging of liver disease, treatments for those newly diagnosed, and those who are dealing with chronic illness, along with managing drug therapy and virus resistance.
Author: Zobair M. Younossi
Publisher: Elsevier Health Sciences
ISBN: 0323532403
Category : Medical
Languages : en
Pages : 217
Get Book Here
Book Description
Dr. Younossi is a highly-esteemed expert in Hepatitis C Virus (HCV), and for the first time in Clinics in Liver Disease, he has compiled articles that specifically address the extrahepatic manifestation of HCV. Articles are specifically devoted to the following topics: Hepatitis C: A Systemic Disease; Rheumatologic Manifestations of HCV; Cardiovascular Manifestations on HCV; Metabolic Manifestations of HCV (DM, Dyslipidemia); Renal Manifestations of HCV; Lymphoproliferative Disorders Associated with HCV; Depression and HCV; Neurologic Manifestations of HCV; Non-HCC Malignancies in HCV; Dermatologic Manifestations of HCV; Fatigue and Patient-reported Outcomes in HCV; Economic Burden of HCV; and Endocrine Manifestations of HCV (non-dabetes). The thorough coverage of systemic issues will give clinicians the information they need to effectively manage the HCV patient with other health issues.
Author: Bandar Al Knawy
Publisher: Elsevier Health Sciences
ISBN: 1455700401
Category : Medical
Languages : en
Pages : 193
Get Book Here
Book Description
This issue offers the latest information regarding the transmission of hepatitis viruses in various healthcare settings. It delves with a very timely and interesting patient safety subject that specifically targets healthcare professionals, gastroenterologists, hepatologists, oncologists, dentists and all healthcare workers to adopt and share a variety of best practices to prevent this adverse event. Well known faculty in liver disease, infection control as well as a medical practice in a legal setting have been assembled to produce a comprehensive and concise edition that highlights the latest information regarding hepatitis B and C transmission in healthcare. It aims to provide an overview on the molecular epidemiology, the outbreak reports, the transmission in hemodialysis, endoscopy, dental, oncology, management, legal aspects and the infection prevention measures to reduce the risk of needless exposure of patients to these blood borne pathogens.